66 results
424B5
RVMD
Revolution Medicines, Inc.
7 Aug 24
Prospectus supplement for primary offering
5:07pm
structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies … resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens.
Our research
S-3ASR
RVMD
Revolution Medicines, Inc.
8 May 24
Automatic shelf registration
5:11pm
capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation … , we deploy precision medicine approaches to inform innovative monotherapy and combination regimens.
Our research and development pipeline comprises
8-K
EX-99.1
RVMD
Revolution Medicines, Inc.
8 May 24
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
4:05pm
, the company has initiated exploratory clinical studies of several combination treatment approaches with these RAS(ON) inhibitors.
“The highly innovative
S-3ASR
2zk2r2o
4 Mar 24
Automatic shelf registration
5:23pm
8-K
EX-99.1
9robcggsf229or24
9 Jan 24
Results of Operations and Financial Condition
2:15pm
425
7q9 gkp2blzc02fg01x
23 Oct 23
Business combination disclosure
6:13am
8-K
EX-99.1
9wo2b
23 Oct 23
Regulation FD Disclosure
6:11am
DEFM14A
5symymsied8mq
29 Sep 23
Proxy related to merger
4:19pm
424B3
p7q7dn
29 Sep 23
Prospectus supplement
4:17pm
S-4/A
wmcid5a8vfqerr8mgx5
27 Sep 23
Registration of securities issued in business combination transactions (amended)
5:25pm
S-4
2c725s
13 Sep 23
Registration of securities issued in business combination transactions
5:20pm
425
90atlw7
1 Aug 23
Business combination disclosure
5:24pm
425
1zg7z
1 Aug 23
Business combination disclosure
5:22pm
425
3dkuzfq4afjil4 zdxum
1 Aug 23
Business combination disclosure
5:13pm